Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation for Treatment of Myelodysplastic Syndromes and Myeloproliferative Disorders (Except CML)
To improve survival outcomes for patients with MDS and MPD with a nonmyeloablative allogeneic hematopoietic cell transplant.
Stanford is not currently accepting new patients for this trial. You may want to check clinicaltrials.gov to see if other locations are recruiting.
- procedure : nonmyeloablative allogeneic hematopoietic cell transplant
Ages Eligible For Study:
- Myelodysplastic Syndromes - Myeloproliferative Disorders - HLA matched donor available